Between 2005 and 2007, mutations in JAK2 and MPL were described in most patients with myeloproliferative neoplasms (MPN). These seminal discoveries have forever changed our diagnostic approach to MPN. In December 2013, mutations in CALR were reported in MPN wild-type for JAK2 and MPL. These mutations provide additional diagnostic and prognostic tools in MPN.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
Molecular Cytogenetics Open Access 17 February 2020
-
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Journal of Hematology & Oncology Open Access 15 July 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tefferi, A., Skoda, R. & Vardiman, J. W. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat. Rev. Clin. Oncol. 6, 627–637 (2009).
James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Eng. J. Med. 369, 2379–2390 (2013).
Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391–2405 (2013).
Vannucchi, A. M. et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27, 1861–1869 (2013).
Rotunno, G. et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood http://dx.doi:10.1182/blood-2013-11-538983.
Tefferi, A. et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia http://dx.doi.org/10.1038/leu.2014.3.
Rumi, E. et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood http://dx.doi:10.1182/blood-2013-11-539098.
Gangat, N. et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29, 392–397 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tefferi, A., Pardanani, A. CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 11, 125–126 (2014). https://doi.org/10.1038/nrclinonc.2014.16
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.16
This article is cited by
-
Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
Molecular Cytogenetics (2020)
-
A rare CALR variant mutation and a review of CALR in essential thrombocythemia
Journal of Thrombosis and Thrombolysis (2018)
-
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Leukemia (2018)
-
Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm
Annals of Hematology (2017)
-
Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Bone Marrow Transplantation (2016)
